Form Type:  SC 13G
Filing Date:  3/13/2018 
CIK:  0001404281 
Address:  19900 MACARTHUR BLVD.
City, State, Zip:  IRVINE, California 92612 
Telephone:  949-238-8090 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
0.34 (5.81%)  
Trade Time: 
Mar 16  
Market Cap: 
Trade NVUS now with 

© 2018  
Description of Business
We are a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases. We have focused substantially all of our research and development efforts on the development of galeterone, an oral small molecule, including clinical trials of galeterone for the treatment of patients with metastatic castration-resistant prostate cancer, or mCRPC. We also have a drug discovery program, known as ARDA (androgen receptor degradation agents), under which we identified novel compounds for patients with androgen receptor signaling diseases, including prostate cancer. In July 2016, we announced our plan to discontinue ARMOR3-SV, our pivotal Phase 3 clinical trial comparing galeterone to Xtandi ® (enzalutamide) in treatment-naïve mCRPC patients whose prostate tumors express the AR-V7 splice variant, following the recommendation made by the trial's independent data monitoring committee, or DMC, in July 2016.
Register and access this filing in: